|
Post by rockstarrick on Mar 3, 2016 11:51:23 GMT -5
Just checked Fidelity, 45%
|
|
|
Post by alethea on Mar 3, 2016 11:59:36 GMT -5
Just checked Fidelity, 45% Thanks! That's what they're paying TO retail shareholders, correct?
|
|
|
Post by dreamboatcruise on Mar 3, 2016 12:32:09 GMT -5
Just checked Fidelity. The rate they are paying longs to borrow shares is 35%. Does anyone know what the current rates are from Fidelity and/or Schwab for borrowing and lending shares to short? Schwab is paying 30%.
|
|
|
Post by saxcmann on Mar 3, 2016 12:32:41 GMT -5
Just checked Fidelity, 45% Thanks! That's what they're paying TO retail shareholders, correct? Correct.
|
|
|
Post by kc on Mar 3, 2016 13:47:19 GMT -5
Just checked Fidelity, 45% Yep but they only have about 60% of my shares on loan.
|
|
|
Post by kc on Mar 3, 2016 13:49:53 GMT -5
Always better with a fresh image of what Fidelity is charging Shorts... As of 3/3/2016
Pressure is mounting. The rate for Shorts to Borrow shares went up again today. that is the 2nd time this week. 53.75%
February 16 the rate was 47.5%
February 12 it was raised to 42.75%
|
|
|
Post by nemzter on Mar 3, 2016 14:12:11 GMT -5
Just checked Fidelity, 45% Yep but they only have about 60% of my shares on loan. 100% still loaned here - kind of odd that yours are only 60%
|
|
|
Post by 4allthemarbles on Mar 3, 2016 15:35:35 GMT -5
At what point does the cost or the risk outweigh the gain? 67%- wow.
|
|
|
Post by kc on Mar 3, 2016 17:11:15 GMT -5
At what point does the cost or the risk outweigh the gain? 67%- wow. Last summer Shake shack was at 95% Not sure where it's at today but that stock took a huge haircut
|
|
|
Post by irrationalexubera on Mar 3, 2016 17:44:55 GMT -5
the lending rate spike historically precludes a new short attack, no? looks like they're setting up for the ER in the next 10 days or so.
|
|
|
Post by sccrbrg on Mar 3, 2016 18:24:29 GMT -5
the lending rate spike historically precludes a new short attack, no? looks like they're setting up for the ER in the next 10 days or so. If MNKD management ever manages to provide good news during a CC it will most likely go the other way. Problem is, we've had wave after wave of bad CC's with little to no good news.
|
|
|
Post by petech on Mar 3, 2016 18:54:20 GMT -5
Last time rates "spiked" by my track was end of May, beginning of June. For Fidelity, that's when they hit a high of 32.75%; briefly (I am speaking only of the to-borrower rates...not the on-lending rates between Fidelity and the shorts). The rate meant a lot more when the stock was at 6-7 a share; which when equivalizing actual payments like paying over 180% interest today (30% interest on $6 share is 1.80 of interest....for $1.80 of interest on a $1 stock, you get 180% interest). Just illustrative...I know there are holes there. Anyway, the key question IMO is what causes the rates to spike...and why this time. When it last spiked it was around the ADA and one would think there was "risk" that things could finally see some pickup in sales. Corrections welcomed: finance.yahoo.com/q/h?s=MNKD&t=2015-06-05So then the question is what about this time? Is there a risk of a deal or some financing? Perhaps...but not in the near term IMO; they still have to get out from under Sanofi's control to seriously consider anything with Afrezza...so will anything happen with Technosphere? Maybe...but as we've seen (in as much as we've seen) with RLS, it doesn't appear we are going to get any cash from that in the short term (would love to be wrong). Will Sanofi negotiate a we-completely-screwed-you-over-let's-not-go-to-court of $100M or so? Maybe (and my hope)...but I don't see that being firmly resolved (i.e., a news release) until they announce their separation on April 4 or so (remember all their confidentiality crap)...if at all, of course. So, yeah I would have to think they're accumulating shares to try and destroy the price when the 10K is released and clearly will have a going concern warning (which Never-Stiff and Fräulein have already written their usual trash about; only question is whether they wait for the news release to pounce or not). Then I see rates dropping back down (shorts covering). Thoughts?
|
|
|
Post by mnholdem on Mar 3, 2016 19:50:11 GMT -5
My thoughts can be summed up in two words: international partners. Of course, if you prefer, you could choose another two words: upfront payments. --- The pundits you refer to can (and likely will) try to dish out their worst, but it will take only one announcement by CEO Pfeffer to demonstrated why those pundits rank near the bottom compared to all investment advisors. Matt's MannKind 2.0 Strategy calls for generating immediate cash via international sales of Afrezza. He spoke about that as if it were low-hanging fruit...very confident! He further disclosed that two regional drug distributors from outside the U.S. called MannKind within 24 hours of the Sanofi termination announcement, looking to reopen negotiations that had been taking place before management decided to sign all Afrezza rights over to Sanofi. Yessir, April 5 is only a few weeks away..."short" weeks. After that, everything may change and those "short" weeks may come to an end, IMHO. Perhaps we'll witness the beginning of an epic comeback.
|
|
|
Post by irrationalexubera on Mar 3, 2016 20:12:39 GMT -5
My thoughts can be summed up in two words: international partners. Of course, if you prefer, you could choose another two words: upfront payments. --- The pundits you refer to can (and likely will) try to dish out their worst, but it will take only one announcement by CEO Pfeffer to demonstrated why those pundits rank near the bottom compared to all investment advisors. Matt's MannKind 2.0 Strategy calls for generating immediate cash via international sales of Afrezza. He spoke about that as if it were low-hanging fruit...very confident! He further disclosed that two regional drug distributors from outside the U.S. called MannKind within 24 hours of the Sanofi termination announcement, looking to reopen negotiations that had been taking place before management decided to sign all Afrezza rights over to Sanofi. Yessir, April 5 is only a few weeks away..."short" weeks. After that, everything may change and those "short" weeks may come to an end, IMHO. Perhaps we'll witness the beginning of an epic comeback. yes, MN, but as pertains to what MNKD can announce at this ER: no afrezza partnerships either in US or ROW, as SNY still owns the product, regardless of MP's behind the scenes negotiations with whomever. all i can see is a discussion of debt and money, since (most likely) the RLS deal is all we'll see for TS this year. if i'm wrong, and there's upfront cash, the SP may spike. outside of that, i would like anyone to illustrate what the company can say that won't be viewed as a death-knell. we all know any next TS candidates are still months away, if even that close. i'm really hoping this is the final ER call where it's all doom and gloom, 'cause MNKD still has their hands mostly tied with afrezza for another few months. (and no, i don't think SNY returns it on 4/5. if they went this far to bankrupt the company, you can bet they'll try to drag it all the way till july and really strap the company for finances.)
|
|
|
Post by centralcoastinvestor on Mar 3, 2016 20:29:46 GMT -5
the lending rate spike historically precludes a new short attack, no? looks like they're setting up for the ER in the next 10 days or so. Is it possible that much of the recent shorting was naked? Perhaps the shorts are having to find actual shares to borrow. Thus driving up the costs to borrow.
|
|